Catégorie : Essais Cliniques

Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder, Emily M. LaFrance et al, 2020,

Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder Emily M. LaFrance, Nicholas C. Glodosky, Marcel Bonn-Miller, Carrie Cuttler Journal of Affective Disorders, 2020, 274, 298–304 Doi : 10.1016/j.jad.2020.05.132   A B S T R A C T Background : Many individuals use cannabis to manage symptoms of post-traumatic stress disorder (PTSD), and evidence indicates that the endocannabinoid system represents a viable target for treating these symptoms. Method : Data from 404 medical cannabis users who self-identified as having PTSD were obtained from Strainprint®, a medical cannabis app that patients use to track changes in symptoms as a function of different strains and doses [...]

Lire la suite

Study finds no evidence marijuana use increases stroke risk, HealthDay News, 2020.

Study finds no evidence marijuana use increases stroke risk HealthDay News, 2020. https://www.upi.com/Health_News/2020/06/04/Study-finds-no-evidence-marijuana-use-increases-stroke-risk/3321591274273/?upi_ss=Cannabis An observational study conducted at hospitals found no evidence that marijuana use increases risk for stroke. File Photo by Atomazul/Shutterstock Whether pot use increases the risk of stroke has been hotly debated, and now a new study adds to evidence that it doesn't. "Our observational study looked specifically at recent cannabis use by reviewing drug testing data for people admitted to the hospital. While more research is needed with larger numbers of people, our study lends support to the studies showing that cannabis use does not increase the risk of stroke," said [...]

Lire la suite

Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health CareWorkers During the COVID-19 Pandemic. A Randomized Clinical Trial, José Alexandre S. Crippa et al, 2021,

Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health CareWorkers During the COVID-19 Pandemic. A Randomized Clinical Trial José Alexandre S. Crippa, PhD; AntonioW. Zuardi, PhD; Francisco S. Guimarães, PhD; Alline Cristina Campos, PhD; Flávia de Lima Osório, PhD; Sonia Regina Loureiro, PhD; Rafael G. dos Santos, PhD; José Diogo S. Souza, MD; Juliana Mayumi Ushirohira, MD, MSc; Julia Cozar Pacheco, RPh; Rafael Rinaldi Ferreira, PhD, RPh; Karla Cristinne Mancini Costa, MSc; Davi Silveira Scomparin, MSc; Franciele Franco Scarante, MSc; Isabela Pires-Dos-Santos, VMD; Raphael Mechoulam, PhD; Flávio Kapczinski, PhD; Benedito [...]

Lire la suite

Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions, Nicole L. Stone et al., 2021

Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions Nicole L. Stone, Timothy J. England, and Saoirse E. O’Sullivan Cannabis and Cannabinoid Research, 2021, Doi : 10.1089/can.2020.0159   Abstract Background and Objectives : Preclinical studies have shown cannabidiol is protective in models of ischemic stroke. Based on results from our recent systematic review, we investigated the effects of two promising neuroprotective phytocannabinoids, cannabigerol (CBG) and cannabidivarin (CBDV), on cells of the blood–brain barrier (BBB), namely human brain microvascular endothelial cells (HBMECs), pericytes, and astrocytes. Experimental Approach : Cultures were subjected to oxygen-glucose deprivation (OGD) protocol to model ischemic stroke and cell [...]

Lire la suite

Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers : pharmaceutical vehicle matters, Jose´A. Crippa et al., 2021

Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters Jose´A. Crippa, Luiz C. Pereira Junior, Livia C. Pereira, Patricia M. Zimmermann, Liberato Brum Junior, Leticia M. Rechia, Isabella Dias, Jaime E. Hallak, Alline C. Campos, Francisco S. Guimaraes, Regina H. Queiroz, Antonio W. Zuardi Brazilian Journal of Psychiatry, 2021, 1-6. Doi : 10.1590/1516-4446-2020-1684   Objective : To compare plasma concentrations of cannabidiol (CBD) following oral administration of two formulations of the drug (powder and dissolved in oil), and to evaluate the effects of these distinct formulations on responses to emotional stimuli in healthy human volunteers. Methods [...]

Lire la suite

New Insights on Hemp Oil Enriched in Cannabidiol: Decarboxylation, Antioxidant Properties and In Vitro Anticancer Effect, Anca Roxana Petrovici et al., 2021

New Insights on Hemp Oil Enriched in Cannabidiol: Decarboxylation, Antioxidant Properties and In Vitro Anticancer Effect Anca Roxana Petrovici, Natalia Simionescu, Andreea Isabela Sandu, Vasile Paraschiv, Mihaela Silion and Mariana Pinteala Antioxidants, 2021, 10, 738. doi : 10.3390/antiox10050738   Abstract : This study aimed to obtain and characterize extracted hemp oil enriched in cannabidiol (CBD) by decarboxylation of cannabidiolic acid (CBDA) and to give new insights into its antioxidant and anticancer effects. Optimization of CBDA decarboxylation in hemp oil was performed, and CBD and CBDA contents and purities were determined by flash chromatography, 1H- and 13C-NMR. The antioxidant properties of CBD-enriched oil were investigated by Fe2+ [...]

Lire la suite

Cannabidiol has a unique effect on global brain activity: a pharmacological, functional MRI study in awake mice, Aymen H. Sadaka et al., 2021

Cannabidiol has a unique effect on global brain activity: a pharmacological, functional MRI study in awake mice Aymen H. Sadaka, Ana G. Ozuna1, Richard J. Ortiz, Praveen Kulkarni, Clare T. Johnson, Heather B. Bradshaw, Bruce S. Cushing, Ai‑Ling Li, Andrea G. Hohmann and Craig F. Ferris Journal of Translationnal Medicine, 2021, 19, 220, 1-16. Doi : 10.1186/s12967-021-02891-6   Abstract Background : The phytocannabinoid cannabidiol (CBD) exhibits anxiolytic activity and has been promoted as a potential treatment for post-traumatic stress disorders. How does CBD interact with the brain to alter behavior? We hypothesized that CBD would produce a dose-dependent reduction in brain activity and functional coupling in [...]

Lire la suite

A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties, Rachael L. Sumner et al., 2021

A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties Rachael L. Sumner, Emme Chacko, Rebecca McMillan, Meg J. Spriggs, Christie Anderson, James Chen, Amelia French, SungHun Jung, Akshaya Rajan, Gemma Malpas, John Hay, Rhys Ponton, Suresh D. Muthukumaraswamy and Frederick Sundram Journal of Psychopharmacology, 2021, 1-16 Doi : 10.1177/0269881121998321 Abstract Background : Ketamine is central to one of the most rapidly growing areas of neuroscientific research into novel treatments for depression. Limited research has indicated that the psychedelic properties of ketamine may play a role in its antidepressant effects. Aim : The aim of the current study was to explore the [...]

Lire la suite

Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease, Stephanie Martins de Faria et al., 2020

Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease Stephanie Martins de Faria, Daiene de Morais Fabrício, Vitor Tumas, Paula Costa Castro, Moacir Antonelli Ponti, Jaime E.C. Hallak, Antonio W. Zuardi, José Alexandre S. Crippa and Marcos Hortes Nisihara Chagas Journal of Psychopharmacology, 2020, 1–8 doi : 10.1177/0269881119895536   Abstract Background : Cannabidiol (CBD) is one of the main components of Cannabis sativa and has anxiolytic properties, but no study has been conducted to evaluate the effects of CBD on anxiety signs and symptoms in patients with Parkinson’s disease (PD). This study aimed to [...]

Lire la suite

MDMA-assisted therapy for severe PTSD : a randomized, double-blind, placebo-controlled phase 3 study, Jennifer M. Mitchell et al., 2021,

MDMA-assisted therapy for severe PTSD : a randomized, double-blind, placebo-controlled phase 3 study Jennifer M. Mitchell, Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman6, Kelly Parker-Guilbert7, Marcela Ot’alora G., Wael Garas, Casey Paleos, Ingmar Gorman 11, Christopher Nicholas12, Michael Mithoefer5,9,13, Shannon Carlin, Bruce Poulter 8,9, Ann Mithoefer9, Sylvestre Quevedo2,14, Gregory Wells 14, Sukhpreet S. Klaire, Bessel van der Kolk16, Keren Tzarfaty9, Revital Amiaz17, Ray Worthy18, Scott Shannon, Joshua D. Woolley2, Cole Marta20, Yevgeniy Gelfand21, Emma Hapke, Simon Amar, Yair Wallach, Randall Brown11, Scott Hamilton25, Julie B. Wang5, Allison Coker 1,5, Rebecca Matthews, Alberdina de Boer5, Berra Yazar-Klosinski, Amy Emerson and Rick Doblin Nature Medicine | www.nature.com/naturemedicine, 2021, 1-12. doi : [...]

Lire la suite